Clinical Trials
7 trialsNCT07060807 2026-06-01
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06434064 2026-04-24
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05748834 2026-03-20
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT05029999 2025-08-13
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT06102824 2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT05159193 2024-02-02
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting